Prognostic significance of the location of lymph node metastases in patients with adenocarcinoma of the distal esophagus or gastroesophageal junction

Annals of Surgery

Volumn 264, Issue 5, 2016, Pages 847-853

  Anderegg, Maarten C J ^a   Lagarde, Sjoerd M ^a,b   Jagadesham, Vamshi P ^b   Gisbertz, Suzanne S ^a   Immanuel, Arul ^a   Meijer, Sybren L ^a   Hulshof, Maarten C C M ^a   Bergman, Jacques J G H M ^a   Van Laarhoven, Hanneke W M ^a   Griffin, S Michael ^b   Van Berge Henegouwen, Mark I ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

(neo)adjuvant treatment; esophageal GEJ adenocarcinoma; location of lymph node metastases; transthoracic esophagectomy

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; OXALIPLATIN; PACLITAXEL; PANITUMUMAB;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; GASTROESOPHAGEAL JUNCTION; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; SURVIVAL TIME; THERMOTHERAPY; ADENOCARCINOMA; CANCER STAGING; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; SECONDARY;

ADENOCARCINOMA; AGED; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING;

EID: 84978663223     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001767     Document Type: Article

References (32)

1. Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: Understanding the rising incidence of this disease. Semin Radiat Oncol. 2013;23:3-9.
2. Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet. 2013;381:400-412.
3. Rusch VW. Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?. Semin Oncol. 2004;31:444-449.
4. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: Esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17:1721-1724.
5. Lagarde SM, Reitsma JB, de Castro SMM, et al. Prognostic nomogram for patients undergoing oesophagectomy for adenocarcinoma of the oesophagus or gastro-oesophageal junction. Br J Surg. 2007;94:1361-1368.
6. Leers JM, DeMeester SR, Chan N, et al. Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg. 2009;138:594-602 [discussion 601-2].
7. Schurr PG, Yekebas EF, Kaifi JT, et al. Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction. J Surg Oncol. 2006;94:307-315.
8. Rüdiger Siewert J, Feith M, Werner M, et al. Adenocarcinoma of the esophagogastric junction: Results of surgical therapy based on anatomical/ topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232:353-361.
9. Grotenhuis BA, Wijnhoven BPL, Poley JW, et al. Preoperative assessment of tumor location and station-specific lymph node status in patients with adenocarcinoma of the gastroesophageal junction. World J Surg. 2013;37:147-155.
10. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol. 2007;8:226-234.
11. Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal cancer: An international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549-556.
12. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol. 2005;6:659-668.
13. Altorki NK, Zhou XK, Stiles B, et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008;248:221-226.
14. Sharma S, Fujita H, Yamana H, et al. Patterns of lymph node metastasis in 3-field dissection for carcinoma in the thoracic esophagus. Surg Today. 1994;24:410-414.
15. Nishimaki T, Tanaka O, Suzuki T, et al. Patterns of lymphatic spread in thoracic esophageal cancer. Cancer. 1994;74:4-11.
16. Castoro C, Scarpa M, Cagol M, et al. Nodal metastasis from locally advanced esophageal cancer: How neoadjuvant therapy modifies their frequency and distribution. Ann Surg Oncol. 2011;18:3743-3754.
17. Prenzel KL, Bollschweiler E, SchröderW, et al. Prognostic Relevance of Skip Metastases in Esophageal Cancer. Ann Thorac Surg. 2010;90:1662-1667.
18. Sobin LH, Compton CC. TNM seventh edition: what's new, what's changed: Communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116:5336-5339.
19. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg. 2007;11:1384-1394.
20. Peters CJ, Hardwick RH, Vowler SL, et al. Generation and validation of a revised classification for oesophageal and junctional adenocarcinoma. Br J Surg. 2009;96:724-733.
21. Talsma AK, Ong CAJ, Liu X, et al. Location of lymph node involvement in patients with esophageal adenocarcinoma predicts survival. World J Surg. 2014;38:106-113.
22. Biere SS, a Y, van Berge Henegouwen MI, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: A multicentre, open-label, randomised controlled trial. Lancet. 2012;379:1887-1892.
23. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718-1723.
24. Boonstra JJ, Koppert LB, Wijnhoven BP, et al. Chemotherapy followed by surgery in patients with carcinoma of the distal esophagus and celiac lymph node involvement. J Surg Oncol. 2009;100:407-413.
25. Sepesi B, Schmidt HE, Lada M, et al. Survival in Patients with Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Ann Thorac Surg. 2016;101:1075-1081.
26. Lagarde SM, Anderegg MCJ, Gisbertz SS, et al. The impact of lymph node metastases near the celiac trunc in patients with cancer of the distal esophagus or gastro-esophageal junction after neo-adjuvant treatment and surgery. ISDE World Conf Abstr. 2014.
27. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol. 2011;12:681-692.
28. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851-856.
29. Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus?. A randomised phase II trial. Eur J Cancer. 2011;47:354-360.
30. Anon. ICORG 10-14: Neo-AEGIS: A randomized clinical trial of neoadjuvant and adjuvant chemotherapy (modified MAGIC regimen) versus neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the esophagus and esophagogastric junction. j 2014 ASCO Annual Me. Available at: Http://meetinglibrary. asco.org/content/130909-144. Accessed January 24, 2016.
31. Shridhar R, Hoffe SE, Almhanna K, et al. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2013;20:3038- 3043.
32. Cichowitz A, Burton P, Brown W, et al. Ex vivo dissection increases lymph node yield in oesophagogastric cancer. ANZ J Surg. 2015;85:80-84.